On 5 December 2017, the European Cancer Patient Coalition (ECPC), in collaboration with the Member of the European Parliament Marlene Mizzi (S&D, Malta) organised an event on the topic of Cancer Biomarkers in the Era of Personalised Medicines.

The event brought together patients, policy-makers, researchers and the industry to discuss the importance of biomarkers for people with cancer, and the necessary actions needed to make precision medicine in cancer a reality across Europe.

Cancer biomarkers are molecules that are usually produced by cancer cells and that can be detected in bodily fluids or tissues. They can identify people who have cancer or who are at risk of getting cancer. Biomarker testing helps to identify the “Achilles' heel” of different types of cancer, ensuring that the right person receives the right treatment at the right time.

The event served also as a launch platform for the ECPC educational video on biomarkers, which will be made available on the ECPC website in January 2018.

The ECPC, through its President and co-founder, Prof. Francesco De Lorenzo, called for more progress to be made towards a harmonised and more efficient regulatory framework which will increase access to and potentially reduce the cost of biomarker testing.

Participants also highlighted the need for increased access and decreased waiting times for high-quality biomarker testing to make personalised healthcare more of a reality.


Download event report below:

Cancer Biomarkers in the Era of Personalised Medicine - Event Report

Download presentations of the speakers below:

The ECPC Call for Action - Francesco De Lorenzo

Personal Testimony - Anne Micallef

The Industry Perspective - Drako Miljkovic

The Importance of Biomarkers for People with Cancer- Nicola Normanno

The Importance of Precision Medicine in Cancer - Mark Lawler

 

 

Event organised thanks to support of: 

 

 

                  Merck logo                   MSD logo logotype              AstraZeneca logo